Anzeige
Mehr »
Mittwoch, 12.11.2025 - Börsentäglich über 12.000 News
BREAKING NEWS: Bohrprogramm gestartet - historisches Uranpotenzial wird jetzt "aufgebohrt"
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von FiercePharma

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
06.10.AstraZeneca, Daiichi score 'landmark' results for ADC Datroway in triple-negative breast cancer
06.10.Myeloid Therapeutics creates new identity after pipeline outgrows its name
03.10.FDA launches generics pilot program, advances facility PreCheck proposal in bid to incentivize US drug manufacturing
03.10.Big Pharma's 'Brexit' draws call for anticompetition probe from advocacy groups: report
03.10.4 reasons why life sciences still fail women at the top, despite a female-majority workforce: report
03.10.Cidara snares up to $339M from BARDA to bankroll its non-vaccine flu candidate
03.10.With FDA approval, Jazz Pharma and Roche's combo sets new bar in first-line small cell lung cancer
03.10.GSK overturns UK watchdog's most serious sanction in COVID press release row
02.10.Vaxcyte strikes up to $1B deal for fill-finish space at Thermo Fisher's NC production facility
02.10.Amgen charts late-stage win for Repatha in broad cardiovascular risk population
02.10.Acadia, e-therapeutics unveil rebrands to better represent their drugmaking missions
02.10.Vanda and the FDA make nice, agreeing to squash several disputes following appeals court win
02.10.AbbVie, BeOne end BTK blood cancer drug patent fight
02.10.Ansa snares $54.4M in series B financing to boost its DNA synthesis platform
02.10.Regulatory tracker: J&J's Tremfya picks up 2 pediatric approvals from FDA
01.10.Halozyme buys subcutaneous drug delivery peer Elektrofi for up to $900M
01.10.Trump's pharma tariffs on hold amid administration's effort to secure pricing concessions, industry investment: Stat
01.10.FDA snubs Cyprium-Sentynl drug for rare pediatric disease due to manufacturing issues
01.10.FDA avoids the worst amid government shutdown, but new applications put on hold
01.10.AbbVie charts next leg of US investment journey with $70M expansion in Mass.
01.10.Bayer consolidates global consumer health marketing, naming IPG as sole creative and media partner
01.10.Sanofi's German, French premises hit by EU probe amid vaccines market abuse concerns
30.09.Indivior to discontinue Opvee marketing after New York settlement
30.09.Novartis earns FDA's ire for 'misleading' romantic storyline of Fabhalta TV ad
30.09.Korea's Boryung looks to stir up new value in Sanofi's legacy chemo Taxotere with $205M rights buy